Document:

ex_357823.htm

Exhibit 4.26

 

 

 

January 13, 2022

 

Ramon Mohanlal

219 west 81 street unit 6D

New York, NY

US 10024

 

Dear Ramon,

 

We would like to thank you for your commitment to BeyondSpring. Your contributions to the organizations are valued, and we look forward to the new year and to working together to make plinabulin available to patients in need.

 

We have had to make the difficult decision to prioritize the Company’s goals and objectives to optimize resources to bring the most value from the plinabulin franchise and patients. We consider you as an important contributor to this more-focused plan, and hope that you will make the commitment to help BeyondSpring achieve its critical clinical and regulatory goals over the next two years. We have great confidence that we have the right plan in place to go forward, and that it will bring success to the plinabulin programs, and to each of us, individually.

 

We are offering several improvements to your compensation and benefits package, as well as a retention package, to help secure your commitment to achieving our two-year goals. A summary of your revised compensation package can be found below. Your entitlement to the all components of the compensation package, including the retention-related provisions, is contingent upon your continued satisfactory job performance. In the event of your termination by the company for reasons other than performance and voluntary resignation, you will still be entitled to receive all components of the Summary of Compensation shown below.

 

We are excited to continue working with you and believe that we can, together, achieve great success for plinabulin and for BeyondSpring!

 

Best regards,

	/s/ Lan Huang	 

Lan Huang, CEO, Chairman and Co-Founder

BeyondSpring Inc.

28 Liberty St. 39th Floor

New York, NY 10005

 

 

 

 

 

 

BeyondSpring Pharmaceuticals, Inc. | 28 Liberty, 39th Floor | New York, NY 10005

Main Tel: (646) 305-6387

www.beyondspringpharma.com

 

 

Compensation and Retention Summary

 

January 13, 2022

Ramon Mohanlal

 

	 	
			●

				
			2021 Base Salary: $_430,000.00_

			

 

	 	
			●

				
			2021 Bonus Award (50% of target): $_96,750.00_ (to be paid approx. February 15,2022)

			

 

	 	
			●

				
			2022 Cost of Living Adjustment (COLA): 4% = $_17,200.00_

			

 

	 	
			●

				
			New 2022 Base Salary: $_447,200.00_

			

 

	 	
			●

				
			2022 Target Performance Bonus, paid in February 2023 (75% cash, 25% options):

			$_150,930.00_ (33.75% of 2022 Base Salary)

			

 

	 	
			●

				
			Retention Bonus (subject continued satisfactory performance): $_387,000.00_ (100% options; 50% payable on 12/31/2022 and 50% payable on 12/31/2023)

			

 

	 	
			●

				
			Company will increase its contribution to cost of medical benefits to 100%.

			

 

	 	
			●

				
			In lieu of the current 401K match in 2022, Company will make a one-time contribution to your 401K retirement savings account equal to 6% of your base salary, up to maximum allowable by IRS regulations.ex_357828.htm

Exhibit 4.27

 

January 13, 2022

Gordon Schooley

11926 Port Labelle Dr

Las Vegas, NV

US 89141

Dear Gordon,

We would like to thank you for your commitment to BeyondSpring. Your contributions to the organizations are valued, and we look forward to the new year and to working together to make plinabulin available to patients in need.

 

We have had to make the difficult decision to prioritize the Company’s goals and objectives to optimize resources to bring the most value from the plinabulin franchise and patients. We consider you as an important contributor to this more-focused plan, and hope that you will make the commitment to help BeyondSpring achieve its critical clinical and regulatory goals over the next two years. We have great confidence that we have the right plan in place to go forward, and that it will bring success to the plinabulin programs, and to each of us, individually.

 

We are offering several improvements to your compensation and benefits package, as well as a retention package, to help secure your commitment to achieving our two-year goals. A summary of your revised compensation package can be found below. Your entitlement to the all components of the compensation package, including the retention-related provisions, is contingent upon your continued satisfactory job performance. In the event of your termination by the company for reasons other than performance and voluntary resignation, you will still be entitled to receive all components of the Summary of Compensation shown below.

 

We are excited to continue working with you and believe that we can, together, achieve great success for plinabulin and for BeyondSpring!

 

Best regards,

	/s/ Lan Huang	 

Lan Huang, CEO, Chairman and Co-Founder

BeyondSpring Inc.

28 Liberty St. 39th Floor New York, NY 10005

 

 

 

 

 

	
			 

			BeyondSpring Pharmaceuticals, Inc. | 28 Liberty, 39th Floor | New York, NY 10005

			Main Tel: (646) 305-6387

			www.beyondspringpharma.com

			

 

 

 

 

Compensation and Retention Summary

 

January 13, 2022

Gordon Schooley

 

	 	
			●

				
			2021 Base Salary: $_300,000.00_

			

 

	 	
			●

				
			2021 Bonus Award (50% of target): $_52,500.00_ (to be paid approx. February 15,2022)

			

 

	 	
			●

				
			2022 Cost of Living Adjustment (COLA): 4% = $_12,000.00_

			

 

	 	
			●

				
			New 2022 Base Salary: $_312,000.00_

			

 

	 	
			●

				
			2022 Target Performance Bonus, paid in February 2023 (75% cash, 25% options): $_81,900.00_ (26.25% of 2022 Base Salary)

			

 

	 	
			●

				
			Retention Bonus (subject continued satisfactory performance): $_210,000.00_ (40% cash, 60% options; 50% payable on 12/31/2022 and 50% payable on 12/31/2023)

			

 

	 	
			●

				
			Company will increase its contribution to cost of medical benefits to 100%.

			

 

	 	
			●

				
			In lieu of the current 401K match in 2022, Company will make a one-time contribution to your 401K retirement savings account equal to 6% of your base salary, up to maximum allowable by IRS regulations.ex_357829.htm

Exhibit 4.28

 

FIRST AMENDED AND RESTATED EMPLOYMENT AGREEMENT

 

 

This First Amendment to Employment Agreement (this “Amendment”) is entered into on January 11, 2022 (the “Effective Date”) by and between BeyondSpring Pharmaceuticals, Inc. (“Company”) and Elizabeth Czerepak (“Employee”) (collectively, the “Parties”).

 

WHEREAS, Employee and the Company entered into an employment agreement on September 11, 2020, in which Employee agreed to serve as an employee of the Company, and

 

WHEREAS, Employee and the Company desire to amend the Employment Agreement to revise certain terms.

 

NOW, intending to be legally bound, the Parties agree as follows:

 

1.           Section 2(b). Section 2(b) is hereby amended and restated in its entirely as follows:

 

(b) Should Employee choose to resign voluntarily from the Company at any point in time, Employee agrees to give the Company a minimum of three (3) months’ written notice prior to Employee’s resignation date.

 

2.           Continuation of Employment Agreement. Except as otherwise expressly provided herein, all of the terms and provisions of the Employment Agreement shall remain in full force and effect.

 

3.           Complete Agreement. This Amendment contains the entire agreement between the Parties hereto with respect to the matters contained herein and supersedes and replaces any prior agreements between the Parties with respect to the matters set forth here.

 

4.           Counterparts. This Amendment may be executed in any number of counterparts and any such counterparts may be transmitted by electronic transmission, and each of such counterparts, whether an original or an electronic or ".pdf" of an original, shall be deemed to be an original and all of such counterparts together shall constitute a single instrument.

 

 

 

IN WITNESS WHEREOF, the Parties have executed this Agreement as of the date first above written.

 

 

 

/s/ Elizabeth Czerepak                 

Elizabeth Czerepak

 

 

/s/ Lan Huang                              

Dr. Lan Huang, CEO

BeyondSpring Pharmaceuticals, Inc.ex_357839.htm

Exhibit 4.29

 

 

January 13, 2022

 

Elizabeth Czerepak

3 Rosemaries Ln

East Hampton, NY

US 11937

 

Dear Elizabeth,

 

We would like to thank you for your commitment to BeyondSpring. Your contributions to the organizations are valued, and we look forward to the new year and to working together to make plinabulin available to patients in need.

 

We have had to make the difficult decision to prioritize the Company’s goals and objectives to optimize resources to bring the most value from the plinabulin franchise and patients. We consider you as an important contributor to this more-focused plan, and hope that you will make the commitment to help BeyondSpring achieve its critical clinical and regulatory goals over the next two years. We have great confidence that we have the right plan in place to go forward, and that it will bring success to the plinabulin programs, and to each of us, individually.

 

We are offering several improvements to your compensation and benefits package, as well as a retention package, to help secure your commitment to achieving our two-year goals. A summary of your revised compensation package can be found below. Your entitlement to the all components of the compensation package, including the retention-related provisions, is contingent upon your continued satisfactory job performance. In the event of your termination by the company for reasons other than performance and voluntary resignation, you will still be entitled to receive all components of the Summary of Compensation shown below.

 

We are excited to continue working with you and believe that we can, together, achieve great success for plinabulin and for BeyondSpring!

 

Best regards,

	/s/ Lan Huang	 

Lan Huang, CEO, Chairman and Co-Founder

BeyondSpring Inc.

28 Liberty St. 39th Floor

New York, NY 10005

 

 

 

 

 

 

BeyondSpring Pharmaceuticals, Inc. | 28 Liberty, 39th Floor | New York, NY 10005

Main Tel: (646) 305-6387

www.beyondspringpharma.com

 

 

 

 

Compensation and Retention Summary

 

January 13, 2022

Elizabeth Czerepak

 

	 	
			●

				
			2021 Base Salary: $_430,000.00_

			

 

	 	
			●

				
			2021 Bonus Award (50% of target): $_96,750.00_ (to be paid approx. February 15,2022)

			

 

	 	
			●

				
			2022 Cost of Living Adjustment (COLA): 4% = $_17,200.00_

			

 

	 	
			●

				
			New 2022 Base Salary: $_447,200.00_

			

 

	 	
			●

				
			2022 Target Performance Bonus, paid in February 2023 (75% cash, 25% options): $_150,930.00_ (33.75% of 2022 Base Salary)

			

 

	 	
			●

				
			Retention Bonus (subject continued satisfactory performance): $_387,000.00_ (40% cash, 60% options; 50% payable on 12/31/2022 and 50% payable on 12/31/2023)

			

 

	 	
			●

				
			Company will increase its contribution to cost of medical benefits to 100%.

			

 

	 	
			●

				
			In lieu of the current 401K match in 2022, Company will make a one-time contribution to your 401K retirement savings account equal to 6% of your base salary, up to maximum allowable by IRS regulations.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00343-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00343-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00343-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00343-of-00352.parquet"}]]